Telix Achieves FY25 Guidance - US$804M, Q4 Growth
Filed with ASX · · 6 pages · English
Watch Telix Pharmaceuticals' latest callTelix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings Call · Replay · Aug 20Read the transcript of Telix Pharmaceuticals (ASX:TLX) Q2 2026 Earnings CallMelbourne (Australia) and Indianapolis, IN (U.S.) – 20 January 2026. Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) provides an update on its commercial and operational performance for the quarter ended 31 December 2025 (Q4 2025). Q4 2025 Highlights • Full-year (FY) 2025 unaudited Group revenue of approximately US$804 million (A$1.2 billion1), in line with upgraded guidance of US$8
Telix Pharmaceuticals Limited on 6ix
Story so far
Earlier from Telix Pharmaceuticals
- Telix Achieves FY 2025 Guidance with US$804M (A$1.2B) Revenue, Accelerates Growth with Gozellix Launch
- Chinese NMPA Accepts New Drug Application for Illuccix
- First U.S. Patient Dosed in BiPASS: Phase 3 Prostate Cancer Diagnosis Study
- Telix to Present Pipeline and Commercial Portfolio Overview at J.P. Morgan Healthcare Conference
- Precision Medicine Portfolio Update
Later from Telix Pharmaceuticals
- First Patient Dosed in Pivotal Phase 3 Study of TLX591-Px (Illuccix®) for Prostate Cancer Imaging in Japanese Patients
- Telix Full Year Results 2025 Investor Webcast Notification
- Telix Submits EU MAA for TLX101-Px Brain Cancer Imaging
- Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
- 2025 Full Year Results Announcement
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals